Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02503358 · ClinicalTrials.gov registry record · Phase 1

Selumetinib and Paclitaxel as Second-Line Treatment in Treating Patients With Stage IIIB-IV Non-small Cell Lung Cancer

A Phase 1 study of Stage IV Non-Small Cell Lung Cancer AJCC v7 and Stage IIIB Non-Small Cell Lung Cancer AJCC v7, sponsored by OHSU Knight Cancer Institute.

Completed
Registry status
Phase 1
Development phase
23
Enrollment target
1
Study location

NCT02503358 is a Phase 1 study of Stage IV Non-Small Cell Lung Cancer AJCC v7 and Stage IIIB Non-Small Cell Lung Cancer AJCC v7 that has completed, run by OHSU Knight Cancer Institute. The registered enrollment target is 23 participants. The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02503358, a Phase 1 study of Stage IV Non-Small Cell Lung Cancer AJCC v7 and Stage IIIB Non-Small Cell Lung Cancer AJCC v7, has completed, sponsored by OHSU Knight Cancer Institute.

COMPLETED
Registry status
Phase 1
Development phase
23 participants
Enrollment target
1
Study location

Study Summary

This randomized phase I trial is studying the side effects and the best dose of selumetinib when given together with paclitaxel as a second line therapy in treating patients with stage IIIB-IV non-small cell lung cancer (NSCLC). Selumetinib may stop or slow the growth of tumor cells by blocking a protein called mitogen-activated protein kinase (MEK) that is needed for cell growth. Drugs used in chemotherapy, such as paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving selumetinib together with paclitaxel may kill more tumor cells.

Conditions Studied

Stage IV Non-Small Cell Lung Cancer AJCC v7 Stage IIIB Non-Small Cell Lung Cancer AJCC v7

Interventions

  • OTHER Laboratory Biomarker Analysis
  • DRUG Paclitaxel
  • DRUG Selumetinib
  • OTHER Pharmacological Study

Study Locations (1)

Oregon

  • OHSU Knight Cancer Institute - Portland

Trial Details

FieldValue
Enrollment Target 23 participants
Start Date 2016-07-21
Est. Completion 2020-07-16
Phase Phase 1

Sponsor

OHSU Knight Cancer Institute

211 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02503358

The ClinicalTrials.gov registry entry for NCT02503358 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is OHSU Knight Cancer Institute, which has 211 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Stage IV Non-Small Cell Lung Cancer AJCC v7 appearing as the primary indexed condition, and to 4 interventions - of which Laboratory Biomarker Analysis is the first listed.

NCT02503358 reports 1 study location spanning 1 distinct geographic area - top geographies include Oregon.

Frequently Asked Questions

What is clinical trial NCT02503358 about?

NCT02503358 is a clinical study titled "Selumetinib and Paclitaxel as Second-Line Treatment in Treating Patients With Stage IIIB-IV Non-small Cell Lung Cancer". This randomized phase I trial is studying the side effects and the best dose of selumetinib when given together with paclitaxel as a second line therapy in treating patients with stage IIIB-IV non-small cell lung cancer (NSCLC). Selumetinib may stop or slow the growth of tumor cells by blocking a pr...

What is the current status of trial NCT02503358?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 23 participants. The study started on 2016-07-21. Estimated completion is 2020-07-16.

What conditions does trial NCT02503358 study?

This clinical trial studies the following conditions: Stage IV Non-Small Cell Lung Cancer AJCC v7, Stage IIIB Non-Small Cell Lung Cancer AJCC v7.

What interventions are being tested in trial NCT02503358?

The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Paclitaxel (DRUG), Selumetinib (DRUG), Pharmacological Study (OTHER).

Who is sponsoring clinical trial NCT02503358?

This trial is sponsored by OHSU Knight Cancer Institute, which has 211 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02503358 being conducted?

This trial has 1 study location across Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Stage IV Non-Small Cell Lung Cancer AJCC v7

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Stage IV Non-Small Cell Lung Cancer AJCC v7

All registered trials for this condition

Stage IIIB Non-Small Cell Lung Cancer AJCC v7

All registered trials for this condition

Oregon

All trials with a study site in Oregon

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.